# TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP)

Study · id `cardio:ct-nct01970215` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01970215](<https://clinicaltrials.gov/study/NCT01970215>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01970215

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 364 participants.

## Technical summary

Registry record NCT01970215. Randomized; quadruple masking; primary purpose treatment. Start 2013-08 (registry gives no type); primary completion 2014-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 364 participants (enrolled count; ClinicalTrials.gov record NCT01970215, source copy `cardio:ctgov-nct01970215-2014-08-21`, retrieved 2026-10-31)
- Start date: 2013-08 (registry gives no type) (ClinicalTrials.gov record NCT01970215, source copy `cardio:ctgov-nct01970215-2014-08-21`, retrieved 2026-10-31)
- Primary completion: 2014-07 (actual) (ClinicalTrials.gov record NCT01970215, source copy `cardio:ctgov-nct01970215-2014-08-21`, retrieved 2026-10-31)
- Completion: 2014-07 (actual) (ClinicalTrials.gov record NCT01970215, source copy `cardio:ctgov-nct01970215-2014-08-21`, retrieved 2026-10-31)
- Countries: Denmark; Netherlands (ClinicalTrials.gov record NCT01970215, source copy `cardio:ctgov-nct01970215-2014-08-21`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01970215-2014-08-21`, retrieved 2026-10-31)

## The registry's words

- Brief title: TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP)
- Acronym: TULIP
- Condition: Dyslipidemia
- Intervention (Drug): TA-8995
- Intervention (Drug): Atorvastatin
- Intervention (Drug): Rosuvastatin
- Intervention (Drug): TA-8995 0mg (placebo)
- Intervention (Drug): Placebo Statin
- Lead sponsor: Xention Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry intervention name matches this record: Atorvastatin (`cardio:atorvastatin`)
- Registry intervention name matches this record: Rosuvastatin (`cardio:rosuvastatin`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial (`cardio:pubmed-26047975`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses (`cardio:pubmed-27678430`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition (`cardio:pubmed-36307922`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: fdadd3ada41d3fe0a9105ea10b39389d7301aadbaa3e2f99ec0426fe52195f09
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
